Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10518725		
	Filing Date		2005-05-26		
INFORMATION DISCLOSURE	First Named Inventor	Danie	l Christopher Brookings		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1625		
	Examiner Name	David	K. O'Dell		
	Attorney Docket Numb	er	CELL-0288 (07-1041-WO-US)		

				U	J.S.P	ATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Pate of cited Docu	entee or Applicant Iment	Relevan		es,Columns,Lines where vant Passages or Releva res Appear	
	1										
If you wisl	h to a	⊥ dd additional U.S. Pate	_ nt citatio	। n informatio	n ple	ease click the	Add button.		Add		
			U.S.P	ATENT AP	PLIC	ATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Releva	•	Lines where	
	1										
If you wisl	h to a	dd additional U.S. Publi	•	•		information p		d button	Add		
				FOREIGIN	TA II	ENI DOCUN		F		umns,Lines	
Examiner Initial*	er Cite Foreign Document Country Number³ Code² i		· I		Publication Date	Name of Patentee or Applicant of cited Document Where Relevance Passages or Figures Appe		evant or Relevant	T5		
	1	WO99/64400	wo			1999-12-16	Vertex Pharmaceut Incorporated	/ertex Pharmaceuticals ncorporated			
	2	WO03/033502	wo			2003-04-24 Celltech R&D Limited		ed			
If you wisl	h to ac	│ dd additional Foreign P	l atent Do	cument cita	tion	information p	Lease click the Add	button	Add		
			NON	I-PATENT L	ITE	RATURE DO	CUMENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10518725		
Filing Date		2005-05-26		
First Named Inventor	Danie	aniel Christopher Brookings		
Art Unit		1625		
Examiner Name	David	David K. O'Dell		
Attorney Docket Number		CELL-0288 (07-1041-WO-US)		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	Henry, J.R. et al., "Potent Inhibitors of the Map Kinase p38", Bioorganice & Medicinal Chemistry Letters, Vol. 8, No. 23, December 1, 1998, pp. 3335-3340.							
	2	Interna	International Search Report PCT/GB03/02667, dated September 24, 2003.						
If you wis	h to a	dd add	itional non-patent literature document citatio	n information please click the Add b	outton Add				
			EXAMINER S	IGNATURE					
Examiner Signature /David O Dell/ Date Considered 04/30/2008									
oitation if I See Kind C Standard ST Kind of doc	not in Codes of (.3). 3 Fourment	confor f USPTO for Japa by the a	reference considered, whether or not citation mance and not considered. Include copy of D Patent Documents at www.USPTO.GOV or MPEP 90 nese patent documents, the indication of the year of the ppropriate symbols as indicated on the document under its attached.	this form with next communication 01.04. ² Enter office that issued the document of the Emperor must precede the ser	to applicant. Int, by the two-letter code (William number of the patent doc	cument.			